Nai-Kong V Cheung

This inventor holds 56 USPTO granted patents and 34 published patent applications, plus 7 CIPO patents and 12 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Memorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Eureka Therapeutics, Inc.. Active years: 1985-2026.

USPTO Granted Patents = 56 (Patent Applications = 34)

% Patents Active = 67.9

CIPO Patents = 7 (Patent Applications = 23)

EPO Patents = 12 (Patent Applications = 35)

Average Co-Inventor Count = 2.0

ph-index = 11

Forward Citations = 372(Granted Patents)

Location History:

Cleveland, OH (US) (1985)
Purchase, NY (US) (2002 - 2023)
New York, NY (US) (2012 - 2024)

Company Filing History:

33 out of 615

Memorial Sloan Kettering Cancer Center

patents

21 out of 517

Sloan-Kettering Institute for Cancer Research

patents

4 out of 52

Eureka Therapeutics, Inc.

Massachusetts Institute of Technology

Health Research, Inc.

patents

8. 1 out of 3,067

The General Hospital Corporation

patents

9. 1 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1985-2026

Loading Chart...

Areas of Expertise:

Cancer Immunotherapy

Bispecific Antibodies

Antibody Multimerization

Diagnostics

Fluorescence Guided Surgery

Radioimmunotherapy

CD33 Antibodies

IL-15 Complexes

Anti-GD2 Antibodies

Vaccine Enhancement

Modular Self Assembly

HLA-restricted Proteins

56 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12729246 - ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF (2026-09-08),

2. 12714758 - DOTA-hapten compositions for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy (2026-08-25),

3. 12630632 - BISPECIFIC HER2 AND CD3 BINDING MOLECULES (2026-05-19),

4. 12533428 - Multimodal fluorine-CY3/5/7-DOTA-hapten compositions, diagnostics, fluorescence guided surgery and radioimmunotherapy (2026-01-27),

5. 12509515 - CD22 ANTIBODIES AND METHODS OF USING THE SAME (2025-12-30),

6. 12497435 - MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY (2025-12-16),

7. 12486323 - ANTI-L1-CAM ANTIBODIES AND USES THEREOF (2025-12-02),

8. 12441793 - CD33 antibodies and methods of using the same to treat cancer (2025-10-14),

9. 12364752 - Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans (2025-07-22),

10. 12343401 - Modular self assembly disassembly (SADA) technologies (2025-07-01),

11. 12195554 - Anti-polysialic acid antibodies and uses thereof (2025-01-14),

12. 11987642 - Bispecific HER2 and CD3 binding molecules (2024-05-21),

13. 11858993 - Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof (2024-01-02),

14. 11820832 - Bispecific HER2 and CD3 binding molecules (2023-11-21),

15. 11673957 - Anti-ROR2 antibodies (2023-06-13),

Title: Nai-Kong V Cheung: Pioneering Innovator in Cancer Research

Introduction:

Nai-Kong V Cheung, a distinguished inventor in the field of oncology, hails from New York, NY, and is renowned for his exceptional contributions to cancer treatment. With an impressive portfolio of 44 patents, his groundbreaking work focuses on developing novel therapies for managing and treating various forms of cancer.

Latest Patents:

Among his recent patents is the innovative "Bispecific HER2 and CD3 binding molecules." These compositions function by targeting the HER2 receptor and CD3, facilitating T cell cytotoxicity to combat disorders like cancer. Additionally, Cheung's "Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex" offer promising prospects for detecting and treating diseases, notably colorectal cancer.

Career Highlights:

Cheung's remarkable career spans prestigious institutions such as the Memorial Sloan Kettering Cancer Center and the Sloan-Kettering Institute for Cancer Research. His relentless pursuit of developing effective cancer therapies has earned him recognition as a leading authority in the field.

Collaborations:

Throughout his career, Cheung has collaborated with esteemed professionals in oncology research. Notable coworkers include Hong Xu and Mahiuddin Ahmed, who have contributed significantly to his innovative projects. Their combined expertise has led to groundbreaking advancements in cancer treatment.

Conclusion:

In conclusion, Nai-Kong V Cheung's dedication to advancing cancer research through innovative patents underscores his unwavering commitment to improving patient outcomes. His pioneering work continues to inspire progress in the field of oncology, offering hope for the future of cancer treatment.